Main Menu

Clinical Trials of Other Treatments

Open to recruitment

CASPS: A Phase II trial of Cediranib in the treatment of patients with Alveolar Soft Part Sarcoma

REACT: REACT is a multicentre, placebo controlled, randomised phase III trial in patients with primary breast cancer. Patients, in addition to their standard adjuvant therapy, are randomised between two years celecoxib (a COX-2 inhibitor) and placebo in a 2:1 ratio in favour of celecoxib.

In active follow-up

HOT: Randomised phase II trial of hyperbaric oxygen therapy for patients with chronic arm lymphoedema after radiotherapy for early breast cancer.

Closed to recruitment

MAPLE: Double-blind short term pre-surgical study to assess the Molecular Antiproliferative Predictors of Lapatinib’s Effects in Breast Cancer.

NICAM: A Phase II Trial of Nilotinib in the treatment of patients with c-KIT mutated advanced acral and mucosal melanoma. NICAM is a single arm Phase II trial for patients with advanced c-KIT mutated acral or mucosal melanoma.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.